Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PCNA | P12004 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100494 | 0.83 | P2RX1 (0.41) | GPR3MAPTWDR5THRATHRB | |
| SCHEMBL24445841 | 0.81 | GPR3 (0.48) | GPR3MAPTWDR5LMNACYP1A2 | |
| SCHEMBL22714098 | 0.81 | GPR3 (0.48) | GPR3MAPTLMNACYP1A2ADORA3 | |
| SCHEMBL13250517 | 0.78 | GPR3 (0.46) | GPR3MAPTWDR5EPHX2KIF11 | |
| SCHEMBL2097133 | 0.78 | APP (0.49) | GPR3MAPTWDR5EPHX2L3MBTL1 | |
| SCHEMBL5024677 | 0.78 | GPR3 (0.46) | GPR3MAPTLMNACYP1A2ADORA3 | |
| SCHEMBL14575001 | 0.76 | THRB (0.54) | MAPTTHRATHRBPOLBPCNA | |
| SCHEMBL1094105 | 0.76 | THRB (0.44) | MAPTTHRATHRBPOLBPCNA | |
| SCHEMBL1275598 | 0.76 | GPR3 (0.44) | GPR3MAPTLMNACYP1A2ADORA3 | |
| SCHEMBL6411536 | 0.76 | GPR3 (0.44) | GPR3MAPTLMNACYP1A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4476222-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| EP-1551836-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551846-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031191-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031190-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6555552-B2 | Psychological disorders; analgesics; antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 2003-04-29 | — | — | US | disclosed |
| US-6479486-B2 | ANTIDEPRESSANTS, ANALGESICS | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | CXCR1, CXCR6, CCR6 | GPR3 268/4885MAPT 4422/4885WDR5 4403/4885 |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | GPR3 3803/4885MAPT 4649/4885WDR5 726/4885 |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | GPR3 16/4885MAPT 4869/4885WDR5 1095/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | GPR3 3705/4885MAPT 4704/4885WDR5 847/4885 |
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | GLRA1, GLRA2, CCKBR | GPR3 242/4885MAPT 4370/4885WDR5 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.